FDA warns India’s Emcure Pharma, cites repeated data fudging at plant
By Zeba Siddiqui MUMBAI (Reuters) – The U.S. Food and Drug Administration (FDA) has warned Indian generic drugmaker Emcure Pharmaceuticals, saying it repeatedly fudged test records at its plant in western India, in another case of a pharmaceutical firm in the country facing such action. In a letter, the FDA said its staff inspected Emcure's plant at Hinjwadi, Pune, where the company makes injectable drugs, between January 27 and February 4 last year and found "significant violations" of standard manufacturing practices. The agency had already banned imports from the plant in July, except for some drugs, such as the cancer medicine carmustine, the antipsychotic haloperidol, and the antibiotic amikacin.
More From Around the Web
Check out these Articles
- The worst Ebola outbreak on record
- 'New day' in lung cancer as Merck drug shines, works with chemo
- Exclusive: GlaxoSmithKline faces fresh drug bribery claims in Syria
- U.S FDA issues draft guidance for abuse-deterrent opioid generics
- Philippines' Duterte threatens to quit U.N. after drugs war censure
- U.S. FDA considers expanding tests for drug residues in milk
- French court finds pharma firm Servier negligent in deadly drug scandal
- California doctor gets 30 years to life in landmark overdose case
- Exclusive: Valeant sends letter to doctors, seeks to reassure over pharmacy...
- BioMarin’s dwarfism drug improves growth in a mid-stage study
- Older Americans taking more medications
- Pfizer’s Xeljanz meets goals in ulcerative colitis trials